focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Re Loaded Agree. Looking forward to next 12 months Heart goes out to imm. holders. Looks like a tough day yesterday On a side note has anyone looked at microbial medicine? Interesting field! https://www.google.co.uk/amp/s/www.bbc.co.uk/news/amp/health-43674270
My thoughts are that perhaps sclp are not willing to sell to pharma yet. Pharma will surely drive a hard bargain as ultimately they want to make massive profit with minimal risk IMO Personally am relieved the funding issue has been dealt with and am in no doubt they will have no problem raising the cash.
https://www.google.co.uk/amp/www.proactiveinvestors.co.uk/companies/amp/news/174558
Meant 'could retrace quite quickly' IMO :)
Found nothing in public domain to account for current sp. My best guess is it's related to sentiment, hence good retrace quite quickly.
http://crimsontide.co.uk/pdf_store/02022017CrimsonTide%20internationalexpansionRNS.pdf
Nice rise on back of today's news! Profit reported to more than double in 2016 http://www.lse.co.uk/AllNews.asp?code=x23e6m07&headline=Crimson_Tide_Profit_To_More_Than_Double_In_2016_As_Revenue_Grows_
Great news!
"This landmark contract is the largest in our history in terms of value and means that mpro5 will be present in nearly 500 more locations throughout the UK. The four-year term represents validation of the partnership we have quickly formed with this well-known retailer. The contract represents another cornerstone of our enterprise level agreement strategy, which now represents a substantial element of our contracted revenues for the coming years," said Chairman Barrie Whipp in a statement. "Following this contract win we are accelerating other expansion plans, both in the UK and overseas," Whipp added. http://www.morningstar.co.uk/uk/news/AN_1476345015210029800/crimson-tide-inks-four-year-gbp17-million-contract-with-uk-retailer.aspx
Great news today! http://www.proactiveinvestors.co.uk/companies/market_reports/167359/risers-fallers-crimson-tide-up-on-contract-win-167359.html
Our view: Venn has started FY 2016 on a strong note. The Company made good progress on both operational and financial fronts. Venn reported a sharp jump in revenue and improved EBITDA for H1 2016. Strong Cash reserves should help the Company deliver on its growth plans. Venn made progress on the integration of Kinesis and achieved initial cross sales. The Company expects to benefit from the acquisition of Kinesis in H2 2016. Venn extended its operating capabilities into the USA with the establishment of Venn Inc and the appointment of a VP of Operations USA. The Company has a solid line of opportunities for H2 2016 and remains fundamentally strong. Therefore, we retain a Speculative Buy rating on the stock' http://www.proactiveinvestors.co.uk/columns/beaufort-securities/26148/beaufort-securities-breakfast-alert-sainsbury-smiths-group-venn-life-sciences-26148.html
Hi my impression is that they are selling as it is loss making to focus on the core business after investment has bought labskin and Clarogel to commercialisation but they are planning on retaining shares so as to maintain access to the upside as this article below puts it In terms of specific figures I've only seen the results and commentary in the annual/interim reports that are available on the internet http://www.ifamagazine.com/market-and-economics/venn-life-sciences-shares-drop-despite-revenue-rise/ Also see comments by Timbo from 30/09 http://uk.advfn.com/stock-market/london/venn-life-VENN/share-chat I've known if him as a poster for a number of years and usually find his comments objective and seemingly well informed Best regards http://uk.advfn.com/stock-market/london/venn-life-VENN/share-chat
Think drop will be very temporary http://www.irishtimes.com/business/health-pharma/income-more-than-doubles-at-clinical-trials-group-venn-1.2808420